80 results
6-K
EX-99
BLRX
Bioline Rx Ltd
10 Apr 14
Current report (foreign)
12:00am
Exhibit 1
For immediate release
BioLineRx Announces Investigator-Initiated Study for
Novel Chronic Myeloid Leukemia Treatment
- Phase 1/2 study … regulatory approval to evaluate BioLineRx’s BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study. BioLineRx is currently
6-K
EX-1
BLRX
Bioline Rx Ltd
6 Sep 11
Orally-Available Molecule for the Treatment of
12:00am
favorable properties from the point of view of bioavailability, safety and efficacy."
"Chronic neuropathic or inflammatory pain is a leading cause … is a complex, chronic state of pain that results from dysfunctional or injured nerve fibers. Neuropathic pain is associated with various conditions
6-K
EX-99
BLRX
Bioline Rx Ltd
5 Mar 12
BioLineRx Receives Approval for Commencing
12:00am
greater efficacy and an improved safety profile."
About Inflammatory Bowel Disease (IBD)
IBD is a chronic, inflammatory, gastrointestinal disease … characterized by chronic abdominal pain, discomfort, bloating and bleeding. The two major types of IBD are ulcerative colitis (UC) and Crohn’s disease
6-K
EX-99
BLRX
Bioline Rx Ltd
17 Sep 13
BioLineRx Announces Receipt of a Notice of Allowance
12:00am
in the development of this promising drug candidate," stated Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx. “HCV induces a chronic …
Hepatitis C infection is a blood-borne infection of the liver caused by the hepatitis C virus (HCV) which becomes chronic in about 85% of cases
6-K
EX-99
BLRX
Bioline Rx Ltd
17 Apr 13
Current report (foreign)
12:00am
with potential co-development and licensing partners for this asset,” concluded Dr. Savitsky.
About Inflammatory Bowel Disease (IBD)
IBD is a chronic inflammatory … gastrointestinal disease characterized by chronic abdominal pain, discomfort, bloating and alteration of bowel habits. Approximately 1-in-500 people
6-K
EX-99
tfkf r852cii1ty
28 Feb 13
Current report (foreign)
12:00am
6-K
EX-99
puak2p7 w3bhgods
16 Oct 12
BioLineRx Announces Successful Completion of Pre-Clinical
12:00am
6-K
EX-99
ojo0e7gm 4j
29 Apr 13
Current report (foreign)
12:00am
6-K
EX-99
nwi1qw1y wyf
8 Jan 14
Current report (foreign)
12:00am
6-K
EX-99
wm575dbj uh4
13 Dec 11
BioLineRx to Develop and Commercialize Novel Peptide
12:00am
6-K
EX-99
ullx1xvfnj
26 Nov 13
Current report (foreign)
12:00am
6-K
EX-99
pt59 a2o0
10 Jun 13
Current report (foreign)
12:00am
6-K
EX-1
4bxagx jmd920y2
26 Sep 11
BioLineRx to Present Data from the Successfully Completed
12:00am
6-K
EX-99
izg i7h6u0ch
7 Mar 12
BioLineRx Announces Grant of European Patent Covering
12:00am
6-K
EX-1
0t5biyta lc
12 Sep 11
BioLineRx Announces Positive Preliminary Results from
12:00am
6-K
EX-99
433tjpfy6zv6vxz3n
5 Jun 12
BioLineRx Announces Receipt of Two Notices of
12:00am
6-K
EX-1
u3a5qbi
11 Jun 14
Current report (foreign)
12:00am
6-K
EX-99
7mrnkz84ge s9s63otwk
5 Dec 11
BioLineRx Announces Positive Final Results from Phase Ia
12:00am
6-K
EX-99
3ljnmmgcqku2jrvq 17p
21 Aug 14
BioLineRx Receives Notice of Allowance for US Patent on BL-7010
12:00am
6-K
EX-99
sc1dqf
23 Jan 12
BioLineRx Signs Exclusive License Agreement
12:00am